Acepodia is applying its ACC™ technology to arm immune cells with antibodies to direct and evoke immune responses to eradicate cancer cells.
Lung cancers, melanoma, head and neck cancer, and other carcinomas
Endometrial cancer, ovarian cancer, breast cancer, gastric cancer
B-cell lymphoma, chronic
Acepodia’s leading clinical product candidate, ACE1702, targets human HER2-expressing solid tumors using anti-HER2 conjugated oNK cells. ACE1702 has demonstrated enhanced tumor cell killing activities both in vitro and in vivo, while maintaining a favorable safety profile in GLP toxicology studies. In preclinical studies ACE1702 has shown enhanced tumor kill efficacy against HER2 IHC 1+, 2+ and 3+ cancer cells, which may have broader coverage on different HER2 expression level carcinoma in treatment compared to Herceptin.
ACE1708, an anti-PD-L1 targeting oNK cell product has shown outstanding anti-tumor activities toward non-small cell lung cancer, bladder cancer, and several additional cancer types with low to high PD-L1 expression in vitro. ACE1708 is a first-in-class immunotherapy which harnesses both NK and T cell capabilities with potential for targeting any PD-L1-expressing cancers.
Lymphoma and Leukemia and other liquid tumors
"We believe what we do is important to the challenges and opportunities of current health care and industries.”
SONNY HSIAO, CEO OF ACEPODIA